Promotional material compliance: digital versus print standards

Promotional assets released for a UK audience therefore required assessment against the updated requirements, including the revised treatment of prescribing information under Clause 12 and the digital controls under Clause 28.1.

The regulatory distinction between print and digital is not a distinction between strict and permissive review. It is a distinction between different failure modes. Print creates a fixed artefact. Digital creates an access pathway, an audience-control problem, and a device-dependent presentation. The medical signatory review must therefore assess more than wording. It must assess the final form, the route to required information, the intended audience, and the consistency of the user experience.

For ABPI Code compliance for digital versus print materials, the central question is not whether the asset is a brochure, banner, website, email, or QR-enabled leavepiece. The central question is whether the final communication preserves the required regulatory information without introducing variance that changes its meaning or accessibility.

The regulatory baseline changed on a fixed date

The 2024 ABPI Code took effect on 1 October 2024. New material standards were subject to a transition period running to 31 December 2024. Full enforcement began on 1 January 2025.

That date is operationally significant. It separates legacy approval logic from current compliance expectations. A promotional asset approved before the transition period cannot be treated as permanently insulated from the revised standard. Continued use creates a current compliance exposure if the material no longer satisfies the applicable requirements.

The update is particularly relevant to Clause 12. Clause 12 addresses prescribing information and other obligatory information. The revised approach permits prescribing information for printed promotional material to be supplied in one of two forms:

1. As text included in the printed material.

2. Through a clear and prominent QR code accompanied by instructions to scan it.

This is not a general permission to remove prescribing information from the asset and replace it with an arbitrary digital reference. The QR code is a controlled delivery mechanism. It must be visible. Its purpose must be intelligible. The recipient must be able to use it within the context in which the material is received.

The distinction affects medical signatory review. Under a text-based print model, the reviewer assesses the wording and placement of the prescribing information in the final static composition. Under a QR model, the reviewer must assess the printed surface and the linked destination as a single compliance system.

The printed asset can be formally complete while the access route fails. A QR code may be technically present but insufficiently prominent. It may direct the user to an inappropriate destination. It may require a second device. It may become disconnected from the version of the prescribing information that was approved. Each condition creates a different variance.

A QR code is not a reduction in regulatory responsibility. It is a transfer of responsibility from the page to the access pathway.

Print remains fixed. QR-enabled print does not.

Traditional print has a narrow compliance perimeter. The relevant questions concern the approved wording, the final artwork, the physical placement of required information, and the audience for which the item was produced.

A printed promotional item can be assessed as a defined artefact. Its dimensions, typography, imagery, claims, and mandatory information are visible in one reviewable form. The medical signatory can determine whether the approved content survives the production process without substantive alteration.

QR-enabled print changes that perimeter. The physical item remains static, but the prescribing information is no longer entirely contained within it. The QR code becomes a functional component of the material. The destination becomes part of the reviewed asset. The user journey becomes relevant.

This creates at least four control points:

• The code must be clear and prominent enough to identify its function.
• The instructions must explain that scanning provides access to the prescribing information.
• The recipient must not be forced to use two separate devices to access the information.
• The destination must present the relevant prescribing information in the form approved for that communication.

The two-device restriction is direct. A QR code cannot be used where the recipient must scan one device with another device, such as scanning a laptop screen with a mobile phone. That condition is structurally different from a printed leaflet or leavepiece held in the recipient’s hand. The access design must operate within the same practical context as the promotional item.

This is where the difference between print and digital becomes less clear. A printed card with a QR code may be classified as print for production purposes, but it contains a digital access mechanism. The review cannot stop at print production controls. It must include the destination and the practical scanning condition.

The compliance standard is therefore determined by function, not by the label attached to the asset.

Clause 12: text inclusion versus QR delivery

The revised Clause 12 approach creates a comparative decision between direct inclusion and linked delivery. Neither option removes the underlying obligation to provide prescribing information. The options differ in how failure can occur.

The table does not imply that text-based delivery is inherently safer. It has its own failure conditions. A dense or poorly positioned block of prescribing information can be difficult to use. A printed version can also become obsolete if the material remains in circulation after a relevant update.

The QR option does, however, add operational dependencies. The approved content exists across more than one controlled component. A change to the destination may affect the compliance status of previously distributed print material. The medical signatory review must establish what was reviewed, what was approved, and how the destination will remain aligned with the approved version.

This is the point at which a basic artwork approval process becomes inadequate. A signatory who reviews only the surface of the print item has not reviewed the complete communication. The review perimeter must follow the route by which the recipient obtains the required information.

Clause 28.1 makes the internet a regulated promotional environment

Clause 28.1 requires promotional material concerning prescription-only medicines directed to a UK audience on the internet to comply with the relevant requirements of the ABPI Code. Digital publication does not create an exemption from the Code. It creates additional variables within the same compliance obligation.

The phrase directed to a UK audience has operational consequences. A company website, campaign landing page, professional portal, digital advertisement, or other online asset may be assessed in the context of its audience and distribution logic. A global website cannot rely on its international structure to avoid UK requirements where promotional material is made available to a UK audience.

The supplementary information to Clause 28.1 addresses audience separation. Unless access to promotional material about prescription-only medicines is restricted to health professionals, company websites must clearly separate sections intended for the public from sections intended for health professionals. The intended audience must also be identified.

This introduces a control that does not have a direct equivalent in a single printed leavepiece. A printed item may be distributed to a defined audience through a controlled channel. An online asset can be reached through search, shared links, campaign activity, or navigation from another page. The audience boundary can become porous.

Digital review must therefore examine:

1. The asset itself.

2. The page or platform on which it appears.

3. The route by which the audience reaches it.

4. The audience classification presented to the user.

5. The controls restricting or separating access.

6. The final impression created by the complete online environment.

A standalone banner may be compliant in isolation and non-compliant in context. A professional page may sit behind a weak audience gate. A public-facing page may link into promotional content intended for health professionals without adequate separation. The medical signatory review cannot treat the page as detached from its navigation and access architecture.

The risk is not limited to an inaccurate claim. The risk includes audience misclassification. The same claim can create a different compliance exposure when presented to the public rather than to health professionals.

Digital compliance fails at the boundary between approved content and uncontrolled access.

Digital versus print review: the object of scrutiny changes

The medical signatory review of promotional assets has a common foundation across media. Claims require substantiation. Mandatory information must be present where required. The overall impression must remain consistent with the approved evidence and the applicable Code.

The review emphasis changes because the media create different forms of variance.

For print, the signatory review is concentrated on the final physical representation:

• Exact wording.
• Claim-to-reference alignment.
• Prominence and legibility.
• Placement of prescribing information.
• Artwork and image selection.
• Audience and distribution context.
• Consistency between approved and produced versions.

For digital media, these controls remain, but the review must extend to the final display and access condition:

• Responsive layout.
• Screen-dependent presentation.
• Links and destination pages.
• Audience segmentation.
• Click or scan pathway.
• Platform-specific functionality.
• Dynamic or changeable content.
• The impression created by the page surrounding the promotional claim.

The PMCPA position is material here. Digital content does not automatically require separate certification for every device type when displayed on commonly used devices such as desktops, tablets, and smartphones. Separate certification is not required solely because the device changes if the final form does not differ substantively in text, artwork, or impression.

The limitation is equally material. If text, artwork, or impression differs substantively across devices, the assumption of a single reviewed form no longer holds. Separate certification is required in that circumstance.

This is not a pixel-count exercise. The relevant threshold is substantive difference. A minor reflow caused by screen width may not create a new communication. A change that removes a qualifier, obscures prescribing information, alters the hierarchy of claims, or changes the overall impression may cross the threshold.

A medical signatory review should therefore distinguish between technical reformatting and regulatory variance. The presence of responsive design is not itself a breach. The failure to assess substantive differences is the control failure.

Device variance is a compliance question, not only a design question

A digital asset may render across multiple devices without identical geometry. That fact alone does not establish non-compliance. The relevant issue is whether the user receives materially different content or an altered impression.

Examples of potentially significant variance include:

• A safety qualifier visible on desktop but displaced below the primary interaction point on a smartphone.
• A claim displayed in full on a tablet but truncated on a smaller screen.
• A prescribing information link visible in one layout but inaccessible or ambiguous in another.
• A professional audience indicator present on one version but absent from another.
• An image or sequence that changes the prominence of a claim.
• A call to action that directs different audiences to different destinations without clear separation.

The review record should identify the devices and environments assessed, but device enumeration alone does not establish control. A list of screenshots is not a substitute for an assessment of substantive difference.

The key variables are:

1. Whether the text remains materially the same.

2. Whether the artwork retains the same regulatory meaning.

3. Whether mandatory information remains accessible.

4. Whether the overall impression changes.

5. Whether the audience designation remains clear.

6. Whether the route to prescribing information functions in the intended context.

A digital approval process that records only the desktop version creates an evidentiary weakness. A process that certifies every device without assessing materiality creates unnecessary duplication. The correct approach is a threshold-based assessment tied to substantive difference.

The two-device rule exposes weak digital design

The restriction on two-device QR access is narrow but consequential. It eliminates a common design assumption: that any visible QR code can be treated as an acceptable route to prescribing information.

A code displayed on a laptop screen may be visually clear. It may resolve to the correct destination. It may function technically. It still cannot satisfy the relevant use condition if the recipient must use a mobile phone to scan the laptop display.

The problem is not the code itself. The problem is the access context.

A compliance assessment should map the expected user journey:

• Where does the recipient encounter the code?
• Is the material physical or displayed on a screen?
• Can the recipient scan it using the same device or within the same practical context?
• Is the instruction understandable?
• Does the destination open directly to the relevant prescribing information?
• Does the process introduce an additional device, login, or navigation barrier?

The two-device rule also demonstrates why digital assets require more than a static visual review. A screenshot cannot prove that the access route satisfies the required condition. The signatory review must include functional evidence or a controlled assessment of the intended journey.

The same principle applies to links. A direct link may be preferable in a digital asset where a QR code would be artificial or operationally weak. The revised Clause 12 treatment of QR codes for printed material does not establish that QR codes can replace direct links in every digital communication. Digital materials require platform-specific assessment.

The channel determines the mechanism. The mechanism does not determine the channel.

Promotional material review must control the final form

The ABPI Code applies to promotional material as experienced by the audience, not merely as drafted by the agency or approved in a document repository. This distinction is central to both print and digital oversight.

For print, the final form includes the production file and the manufactured item. A last-minute artwork change can alter the placement of a mandatory statement. A print vendor substitution can affect legibility. A reduced format can compress information beyond practical use. These are final-form risks.

For digital, the final form is less stable. It may include the page, the device, the browser, the platform, the navigation path, and the linked destination. A content management change can alter a sentence after signatory review. A link can resolve to a different page. A campaign parameter can route different audiences to different content. A responsive component can change the presentation at a defined viewport.

The compliance control therefore requires version governance. The following elements should remain connected:

• Approved source content.
• Approved artwork or page design.
• Approved audience classification.
• Approved prescribing information.
• Approved links and destinations.
• Approved device or display assumptions where relevant.
• Release date and withdrawal controls.
• Evidence of the final deployed version.

This is not administrative excess. It is the minimum structure required to establish what was reviewed and what the audience received.

A print approval without production control is incomplete. A digital approval without deployment control is incomplete. In both cases, the gap is traceability.

Comparative compliance standards for pharma marketing materials

The practical comparison can be reduced to a sequence of cause and effect.

1. The asset is classified by its communication function

A brochure, website, banner, email, QR-enabled card, and professional portal may have different formats. Classification should begin with what the asset communicates, to whom, and through which route.

Format is relevant. It is not decisive.

2. The mandatory information route is identified

The asset may contain prescribing information directly or provide access through an approved mechanism. The route must be visible, usable, and consistent with the medium.

A QR code on a printed item is not equivalent to a link on a digital page. The user conditions differ.

3. The audience boundary is assessed

If the digital asset concerns a prescription-only medicine and is directed to a UK audience, Clause 28.1 applies. Where content is not restricted to health professionals, public and professional sections must be clearly separated and the intended audience identified.

Audience control is part of content control.

4. The final display is tested for substantive variance

Desktop, tablet, and smartphone presentation can be covered by one certification where the final form does not differ substantively in text, artwork, or impression. Where it does differ, separate certification becomes necessary.

The threshold is substantive difference, not device count.

5. The release state is controlled

The approved version must correspond to the deployed or distributed version. A digital asset that can change without re-review has an uncontrolled compliance perimeter. A print asset reproduced after artwork changes has the same defect in physical form.

This sequence applies equally to medical affairs promotional material approval and commercial promotional review. The difference lies in how much of the communication is fixed at the point of approval.

The 2025 enforcement standard changes the treatment of legacy assets

The end of the transition period creates a review requirement for assets that remain in use. The relevant question is not when the asset was first approved. It is whether the asset continues to satisfy the applicable standard after 1 January 2025.

A legacy print item with embedded prescribing information may require reassessment against the revised Clause 12 requirements, particularly if it is being reproduced or materially altered. A print item using a QR code requires a further assessment of whether the code, instructions, and destination satisfy the current conditions.

Digital assets require a more active review because their state can change without a new print run. Landing pages, banners, portals, and campaign destinations can remain accessible after the internal campaign has been considered complete. The continued availability of the content can preserve the compliance exposure.

A focused transition review should establish:

• Which assets remain publicly or professionally accessible.
• Which assets concern prescription-only medicines.
• Which assets are directed to a UK audience.
• Whether the intended audience is clearly identified.
• Whether the asset uses a QR code or other route to prescribing information.
• Whether the route requires two devices.
• Whether the digital presentation changes substantively across commonly used devices.
• Whether the deployed content matches the approved content.
• Whether obsolete assets have been withdrawn or replaced.

The review should not rely on a generic statement that an asset was previously approved. Prior approval is evidence of a historical decision. It is not proof of current compliance.

A defensible signatory review records variance and mitigation

The strongest medical signatory review is not the one with the largest number of signatures. It is the one that defines the compliance perimeter and records the material decisions within it.

For print, the record should show how the final artwork was controlled and how required information was presented. For QR-enabled print, it should also show the destination and the conditions under which the code is used.

For digital content, the record should show the audience, channel, final form, device assessment, links, and destination content. Where no separate certification is made for each device, the basis should be clear: no substantive difference in text, artwork, or impression.

The relevant concepts are variance, threshold, and mitigation.

• Variance identifies where the asset changes across formats, devices, or access routes.
• Threshold determines whether the change is substantive enough to require additional certification or control.
• Mitigation addresses the identified exposure through redesign, audience restriction, direct access, corrected prescribing information, withdrawal, or re-review.

This approach prevents two opposite failures. The first is under-control: treating digital content as a static page and missing material differences. The second is over-control: certifying every technical variation without determining whether the regulatory impression changes.

Both failures waste review capacity. Only one creates a defensible approval record.

Final assessment

The comparison between digital and print promotional standards is not a contest between higher and lower regulatory scrutiny. Print concentrates risk in the fixed artefact. Digital distributes risk across content, audience, device, link, platform, and destination.

The 2024 ABPI Code makes that distinction operational. Clause 12 permits QR-based delivery of prescribing information for printed promotional materials, subject to clear presentation, instructions, and a usable access context. Clause 28.1 applies the Code to internet promotion directed to a UK audience and requires controlled separation where public and health professional content coexist. Device variation does not automatically require separate certification, but substantive differences in text, artwork, or impression cross the relevant threshold.

The compliance position is therefore definitive. A print asset can be approved only as the final printed communication. A digital asset can be approved only as the final digital experience. Any medical signatory review that excludes the route by which the audience receives required information leaves a quantifiable gap in control.

That gap is the risk.